2025 SCRS Eagle Awards Presented to Merck and Medpace

October 13, 2025 – The Society for Clinical Research Sites (SCRS) proudly announces the 2025 recipients of the prestigious SCRS Eagle Award: Merck (known as MSD outside the United States and Canada) in the sponsor category and Medpace in the CRO category.

Now in its 16th year, the SCRS Eagle Award celebrates outstanding collaborations between clinical research sites and their sponsor and CRO partners. Proudly sponsored by Advarra, this distinguished recognition highlights organizations that demonstrate leadership, professionalism, integrity, passion, and commitment to enhancing clinical research through meaningful site partnerships.

Research sites globally participated in the annual SCRS Eagle Award survey to evaluate sponsor and CRO partners who consistently demonstrate excellence across multiple operational areas. This year’s comprehensive voting process engaged nearly 2,000 sites, who assessed over 16,300 active data points based on their experience working together over the past 12 months.

Through the survey, nominees were scored across key operational categories including business development, budgeting approach, contract language, payment process, communication, efficient start-up, support for research participants from all communities, and effective use of technology. The recipient sponsor and CRO were selected based on their overall performance rankings from this extensive community assessment.

Merck team accepting the 2025 Eagle Award

Jennifer Sheller, Senior Vice President and Head, Global Clinical Trial Operations at Merck shared, “Our company is deeply honored to receive the Eagle Award, a reflection of the invaluable partnership we share with clinical trial sites around the world. Sites are the heartbeat of clinical research. Their dedication, resilience and unwavering focus on patients make progress possible. We remain committed to empowering sites to focus on what truly matters: the rights, safety and well-being of every participant. By prioritizing critical to quality factors and removing unnecessary complexity, we aim to make research more agile, inclusive and impactful. Together, we are not just running trials – we are delivering hope through collaboration, urgency and purpose to turn scientific discovery into life-changing medicines and vaccines for patients and caregivers around the world.”

Medpace team accepting the 2025 Eagle Award

“Medpace is thrilled to receive the 2025 Eagle Award”, said Gina Leisring, Sr. Vice-President, Clinical Monitoring at Medpace. “This recognition reflects our commitment to building exceptional partnerships with sites around the world. We would like to express our gratitude to the sites who play an essential role in effective clinical development, helping us bring new and innovative therapies to patients in need.”

Sean Soth, SVP of Global Business Partnerships with SCRS added, “SCRS congratulates Merck and Medpace as the 2025 Eagle Award recipients, a recognition that comes directly from the global site community. Nearly 2,000 sites shared 16,300+ real-world data points about their experiences, and these organizations scored well across all categories within the SCRS Eagle Award survey. In an industry where collaboration is a critical success factor for patient outcomes, Merck and Medpace have proven that exceptional site partnerships aren’t just good business, they’re essential for advancing clinical research that changes lives. Congratulations to both organizations for outstanding efforts to elevate site collaboration.”

Both awards were presented during the 2025 SCRS Global Site Solutions Summit Eagle Award Gala, sponsored by Advarra. Additional information about the SCRS Global Site Solutions Summit and Eagle Award can be found at sitesolutionssummit.com/global.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,000 people across 44 countries as of June 30, 2025. Learn more at medpace.com.